Navigation Links
Dr. Douglas Wallace to receive Gruber Foundation 2012 Genetics Prize
Date:6/29/2012

Douglas C. Wallace, Ph.D., director of the Center for Mitochondrial and Epigenomic Medicine at The Children's Hospital of Philadelphia, will receive the 2012 Genetics Prize of The Gruber Foundation. This prestigious international awarda $500,000 prizerecognizes Wallace's pioneering scientific investigations of the wide-ranging role of mitochondria in the development of disease and as markers of human evolution. Mitochondria are the tiny power plants within the cytoplasm of animal and plant cells.

Wallace will receive the award on November 9 at the annual meeting of the American Society of Human Genetics in San Francisco. The Gruber Foundation, now based at Yale University, announced the Genetics Prize on June 28. The Foundation's Genetics Prize annually honors leading scientists for groundbreaking contributions to genetics research.

Philip R. Johnson, MD, chief scientific officer at The Children's Hospital of Philadelphia, acknowledged Wallace's achievements, saying, "The Children's Hospital of Philadelphia Research Institute is privileged to number Douglas Wallace among our research leaders. His commitment to the field of mitochondrial genetics and his pioneering nature embody the mission of research at CHOP, and his research and leadership are shaping the way we approach therapies for genetic disorders previously considered beyond treatment."

"Douglas Wallace's contributions to our understanding of mitochondrial genetics have changed the way human and medical geneticists think about the role of mitochondria in human health and disease," said Dr. Elizabeth Blackburn, chair of the Selection Advisory Board to the Prize. Blackburn, who shared the 2009 Nobel Prize in Physiology or Medicine, also received the Gruber Genetics Prize in 2006.

Wallace, who came to The Children's Hospital of Philadelphia in 2010 to launch the Center for Mitochondrial and Epigenomic Medicine, first achieved prominence in the 1970s as the leader of a research team at Stanford University that defined the genetics of mitochondrial DNA. This DNA resides within each mitochondrion, as distinct from the more familiar nuclear DNA inside chromosomes. His group showed that human mitochondrial DNA is inherited exclusively from the mother.

This discovery, coupled with other findings, allowed the researchers to reconstruct ancient human migration patterns over hundreds of millennia, a major contribution that bridges genetics and anthropology. Wallace and colleagues also have linked mutations in mitochondrial DNA to a broad range of human diseases, including types of blindness, deafness, metabolic disorders such as diabetes, neuropsychiatric conditions, and age-related diseases such as heart disease and cancer.

The Center for Mitochondrial and Epigenomic Medicine at Children's Hospital researches mitochondrial dysfunction in many clinical problems, and also focuses on preclinical studies relevant to developing therapies for mitochondrial diseases, for which few effective clinical treatments currently exist.

Wallace holds the Michael and Charles Barnett Endowed Chair in Pediatric Mitochondrial Medicine at Children's Hospital and also is a professor of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania. He is a member of the National Academy of Sciences, the nation's premier organization of leading researchers, as well as the Academy's Institute of Medicine, and is also a member of the American Academy of Arts and Sciences.


'/>"/>

Contact: Dana Mortensen
mortensen@email.chop.edu
267-426-6067
Children's Hospital of Philadelphia
Source:Eurekalert

Related biology news :

1. 3-V Biosciences Appoints Douglas I. Buckley, PhD, as Vice President of Biology
2. University of Tennessee professor receives funding for clean coal research
3. UC Riverside geologist receives 2 prestigious honors
4. Argonne researchers receive 4 R&D 100 awards
5. AcelRx Pharmaceuticals Receives First U.S. Patent for Small-Volume Oral Transmucosal Dosage Forms
6. UCLAs Yi Tang receives Presidential Green Chemistry Challenge Award from EPA
7. Researchers at GW receive federal funds to study the effect earthquakes have on nuclear reactors
8. Leading statistician receives national citation award
9. Dr. Karen Lloyd receives WHOIs Holger W. Jannasch Visiting Scholar Award
10. SF State biology department receives $1.5 million to support science teaching
11. SRI Sarnoffs Iris on the Move® N-Glance™ Identification System Receives Lenel Factory Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... The ... endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. ... is transformative for performing systematic gain-of-function studies. , This complement to loss-of-function ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017  SkylineDx ... London (ICR) and University of Leeds ... to risk-stratify patients with multiple myeloma (MM), in a multi-centric ... The University of Leeds is the ... UK, and ICR will perform the testing services to include ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
(Date:10/10/2017)... BARBARA, CALIFORNIA (PRWEB) , ... October 10, 2017 ... ... management, technological innovation and business process optimization firm for the life sciences and ... BoxWorks conference in San Francisco. , The presentation, “Automating GxP Validation ...
Breaking Biology Technology: